Drug or intervention
flow cytometry Clinical Trials
Studies that test flow cytometry, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 111Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Background: Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers.
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL)
- Trial name
- NCT01087333
- Where
- United States
- Volunteers
- 1,263 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Diminished Ovarian Reserve (DOR)
Application of Autologous Adipose Stromal Vascular Fraction in the Treatment of Diminished Ovarian Reserve
A multi-center, prospective, randomised controlled clinical trial (1:1 treatment ratio), designed to investigate the efficacy and safety of autologous SVF in improving the pregnancy outcome of infertile patients with DOR.
- Trial name
- aSVF-DOR (NCT07901218)
- Testing
- Lower abdominal liposuction and preparation of SVF, Ovarian injection, Conventional ART treatment
- Where
- 4 sites in China
- Volunteers
- 260 people
- Sponsor
- Peking University Third Hospital
Sepsis
Clinical Value of EMR3 in Sepsis Diagnosis, Monitoring, and Prognosis: A Multicenter Prospective Observational Study
Sepsis is a life-threatening condition caused by a dysregulated immune response to infection, leading to organ dysfunction and increased mortality.
- Trial name
- EMR3-SEPSIS (NCT07896018)
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sir Run Run Shaw Hospital
Prostate Cancer
Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA)
This monocentric interventional study investigates whether the Radio-induced Lymphocyte Apoptosis (RILA) assay can predict the occurrence of late radiation-induced toxicities in patients with localized prostate cancer treated…
- Trial name
- PROSTERA (NCT07145437)
- Testing
- Radio-induced Lymphocyte Apoptosis (RILA) Assay, Stereotactic body radiotherapy (SBRT)
- Volunteers
- 220 people
- Sponsor
- Clinique Sainte Clotilde
Acute Myeloid Leukemia, Myeloid Hematological Malignancies
Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry
CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies.
- Conditions
- Acute Myeloid Leukemia, Myeloid Hematological Malignancies, Normal Hematopoietic Stem and Progenitor Cells
- Trial name
- MYEL-CD180 (NCT07895901)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Hematologic Malignancies, Hematologic Neoplasms
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone.
- Trial name
- NCT07162038
- Testing
- mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer (Diagnosis)
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, >6 to <30 mm in Diameter, Determined by LDCT.
- Trial name
- BA-004 (NCT07168993)
- Testing
- Standard medical treatment
- Where
- 11 sites in United States
- Volunteers
- 2,063 people
- Sponsor
- bioAffinity Technologies Inc.
Hematologic Malignancy, Leukemia
Better Leukemia Diagnostics Through AI (BELUGA)
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms.
- Conditions
- Hematologic Malignancy, Leukemia, Minimal Residual Disease, Lymphoma
- Trial name
- BELUGA (NCT04466059)
- Testing
- Automated AI-Guided Diagnosis of Hematological Malignancies
- Where
- Germany
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Munich Leukemia Laboratory
Critical Illness, Intensive Care Patients
IMMUNOREA - Immunological and Inflammatory Determinants Associated With the Prognosis of Intensive Care Patients
This is a prospective observational physiopathological study aimed at evaluating the immunological and inflammatory determinants associated with the prognosis of patients admitted to intensive care units (ICU).
- Conditions
- Critical Illness, Intensive Care Patients, Critical Illness Requiring Intensive Care - Sepsis, Critical Illness Requiring Intensive Care - Acute Brain Injury
- Trial name
- IMMUNOREA (NCT07345169)
- Where
- France
- Volunteers
- 540 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B Cell Lymphoma, Multiple Mieloma
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints.
- Trial name
- CARBIOM (NCT07852377)
- Testing
- Biological sample collection and immunomonitoring
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
Completed, with results posted
All 40Acute Lymphoblastic Leukemia, Pediatric
Vaccine Immune Recovery After Leukemia
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia…
- Trial name
- VIRAL (NCT05622682)
- Testing
- Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
- Where
- 6 sites in United States
- Volunteers
- 89 people
- Sponsor
- Children's Hospital of Philadelphia
Multiple Myeloma
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
This study was a multi-center, open-label, single-arm, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 46 subjects were enrolled.
- Trial name
- NCT02969837
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- University of Chicago
Multiple Myeloma
Short Course Daratumumab in Patients With Multiple Myeloma
The purpose of this study is to test the safety of short course Daratumumab in combination with lenalidomide and to find out what effects, if any, short course Daratumumab in combination with lenalidomide has on people and their…
- Trial name
- NCT03490344
- Testing
- Daratumumab, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Cancer
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00410956
- Testing
- bevacizumab, dexamethasone, floxuridine
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndromes
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00382200
- Testing
- decitabine, tretinoin, DNA methylation analysis
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center